Compare XMTR & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | MMED |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2021 | 2026 |
| Metric | XMTR | MMED |
|---|---|---|
| Price | $82.20 | $14.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $58.60 | $22.56 |
| AVG Volume (30 Days) | ★ 893.6K | 818.9K |
| Earning Date | 05-07-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $686,631,000.00 | N/A |
| Revenue This Year | $23.76 | $15.99 |
| Revenue Next Year | $18.38 | $10.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.87 | N/A |
| 52 Week Low | $29.60 | $10.65 |
| 52 Week High | $99.86 | $17.86 |
| Indicator | XMTR | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 67.73 |
| Support Level | $56.76 | $12.80 |
| Resistance Level | $99.86 | $15.80 |
| Average True Range (ATR) | 4.61 | 0.88 |
| MACD | -2.59 | 0.48 |
| Stochastic Oscillator | 21.43 | 90.86 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.